[{"from": "human", "value": "Describe this molecule. [C][C][C@H1][Branch1][C][C][C@H1][C][=Branch1][C][=O][N][C@H1][Branch2][#Branch1][=C][C][=Branch1][C][=O][N][C@H1][Branch2][=Branch1][#C][C][=Branch1][C][=O][N][C@@H1][Branch2][Ring2][Ring2][C][S][S][C][C][C][=Branch1][C][=O][N][C@@H1][Branch1][=Branch2][C][=Branch1][C][=O][N][Ring2][Ring1][=Branch2][C][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][C][C][=Branch1][C][=O][N][C][C][C][C@H1][Ring1][Branch1][C][=Branch1][C][=O][N][C@@H1][Branch1][Branch1][C][C][C][N][C][=Branch1][C][=O][N][C][C][=Branch1][C][=O][N][C][C][=Branch1][C][=O][N][C@@H1][Branch1][C][C][O]"}, {"from": "gpt", "value": "The molecule is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985. Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women."}]